Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin, Huons Sign Deal To Commercialize Cyclosporine in Mexico
Details : The agreement aims for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion, generic of Restasis, in Mexico.
Brand Name : Restasis-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : LIPAC Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons
Details : Clinical Study Report for a Phase 2A marker lesion clinical trial in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer treated with LiPax has been finalized. First milestone payment to LIPAC under the collaboration signed in In ...
Brand Name : LiPax
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : LIPAC Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
